Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 60 resultados
LastUpdate Última actualización 26/02/2026 [07:12:00]
pdfxls
Solicitudes publicadas en los últimos 90 días / Applications published in the last 90 days
previousPage Resultados 25 a 50 de 60 nextPage  

用于检测产志贺毒素大肠杆菌和/或肠出血性大肠杆菌的反应培养基及方法

NºPublicación:  CN121399274A 23/01/2026
Solicitante: 
生物梅里埃公司
CN_121399274_A

Resumen de: WO2025003117A1

The present invention relates to a gelled reaction medium for detecting, identifying, and/or isolating at least one Shiga toxin-producing strain of E. coli, the reaction medium comprising: - at least one toxin inducer, - at least one agglutinating conjugate comprising at least one specific binding partner of STX1 and/or at least one specific binding partner of STX2, coupled to a nanoparticle; - a concentration gradient of a compound for inhibiting non-target bacteria. The present invention also relates to the associated method for detecting and/or isolating Shiga toxin-producing E. coli which is likely to be present in a sample comprising enterobacteria.

SCREENING OR SELECTION MEDIUM COMPOSITION FOR SALMONELLA

NºPublicación:  KR20260011330A 23/01/2026
Solicitante: 
최희정최완수최수연

Resumen de: KR20260011330A

본 발명은 프로테오즈 펩톤, D-소르비톨, 페놀 레드, 뉴트럴 레드, 크리스탈 바이올렛 및 사카로스를 포함하는 살모넬라 균의 선별 또는 선택 배지 조성물에 관한 것이다.

Complejo proteico antibacteriano.

NºPublicación:  CL2025002347A1 23/01/2026
Solicitante: 
THE UNIV COURT OF THE UNIV OF GLASGOW [GB]
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIV OF OXFORD [GB]
THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW,
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
JP_2026504503_PA

Resumen de: CN120917035A

The present invention relates to protein bacteriocins (PBs) as therapeutic agents, and in particular to protein complexes comprising two or more PB molecules associated with a protein scaffold comprising a homologous immune protein domain against an effector portion of the corresponding PB. In particular, the present invention provides an antibacterial protein complex comprising: (a) a first PB molecule and a second PB molecule; and (b) an immune protein scaffold comprising a first immune protein domain and a second immune protein domain; wherein the first immune protein domain and the second immune protein domain are non-covalently bound to the first PB molecule and the second PB molecule, respectively.

RECOMBINANT EXPRESSION VECTOR FOR VC1 SECRETION, AND ATTENUATED SALMONELLA STRAIN TRANSFORMED THEREWITH

NºPublicación:  US20260021146A1 22/01/2026
Solicitante: 
THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIV IAC [KR]
KOREA INSTITUTE OF SCIENCE AND TECH [KR]
THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC),
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
US_20260021146_PA

Resumen de: US20260021146A1

The present disclosure relates to a recombinant expression vector for secretion of a VC1 protein and an attenuated Salmonella strain transformed therewith, and provides: a recombinant expression vector comprising an flgM gene, a VC1 gene, and an flhDC gene; an attenuated Salmonella strain transformed therewith; and a pharmaceutical composition for cancer treatment, comprising the attenuated Salmonella strain.

FORT’S DRY AND HOLD PAIL

NºPublicación:  US20260022888A1 22/01/2026
Solicitante: 
BRIGGS PAULETTE NICOLE [US]
Briggs Paulette Nicole
US_20260022888_PA

Resumen de: US20260022888A1

The purpose of the (Fort's Gloves, Dry and Hold Pail) is to prevent moisture that causes the spread of bacteria from restrooms that is the cause of influenza, streptococcus, E coli, Hepatitis, MRSA, Salmonella, Shigella, and Norovirus. The pail is a new creation except for the authentic manuscript and cursive text. There is a distinct difference from the usual and traditional utility pails each community uses, because of the holder for the moisture elimination products that prevents contaminated water from spilling to the floor. Fecal and Trash water could potentially cause mildew growth on the gloves and the pail. The Dry & Hold container overall is a new Invention and a cleaner choice for the environment because the design prevents disease, foul odors.

RECOMBINANT EXPRESSION VECTOR FOR MELITTIN SECRETION AND ATTENUATED SALMONELLA STRAIN TRANSFORMED THEREWITH

NºPublicación:  US20260022390A1 22/01/2026
Solicitante: 
THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIV IAC [KR]
THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
US_20260022390_PA

Resumen de: US20260022390A1

The present disclosure relates to a recombinant expression vector for secretion of melittin and an attenuated Salmonella strain transformed therewith, and provides an attenuated Salmonella strain transformed with a recombinant expression vector including an flgM gene and a melittin gene, an anticancer pharmaceutical composition including the attenuated Salmonella strain as an active ingredient, and a recombinant expression vector capable of improving the secretion ability of melittin.

IMMUNOGENIC COMPOSITIONS

NºPublicación:  EP4680273A1 21/01/2026
Solicitante: 
AFFINIVAX INC [US]
Affinivax, Inc
CN_120826235_PA

Resumen de: CN120826235A

Techniques for providing immunogenic compositions (e.g., vaccines) and methods of inducing an immune response in a subject in need thereof are provided.

SYNTHETIC GENE CLUSTERS

NºPublicación:  US20260015620A1 15/01/2026
Solicitante: 
THE REGENTS OF THE UNIV OF CALIFORNIA [US]
The Regents of the University of California
US_20260015620_A1

Resumen de: US20260015620A1

Methods for making synthetic gene clusters are described.

INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME

NºPublicación:  US20260007731A1 08/01/2026
Solicitante: 
BLUEWILLOW BIOLOGICS INC [US]
BLUEWillow Biologics, Inc,
BlueWillow Biologics, Inc
US_20260007731_PA

Resumen de: US20260007731A1

The present invention relates to intranasal bacterial polysaccharide conjugate nanoemulsion vaccines and methods of using the same for inducing an immune response to a bacterial polysaccharide.

SYSTEMS AND METHODS FOR RISK ASSESSMENT FOR ZOONOTIC DISEASE IN ANIMAL POPULATIONS

NºPublicación:  AU2024277588A1 08/01/2026
Solicitante: 
ELANCO US INC
ELANCO US INC
AU_2024277588_PA

Resumen de: AU2024277588A1

Systems and methods for assessing risk for zoonotic disease, including salmonella, amongst an animal population at a production facility. A user can provide data in response to a plurality of data entry fields that can, at least partially, pertain to a procedure, operation, and/or equipment at the production facility. For each data entry field, the data provided by the user can be assigned a value. The value can correspond to predetermined value of a predetermined response that is identified as corresponding to the user inputted data. The assigned value can be adjusted by a weighted factor, which may correspond to a predicted impact the actions or information reflected by the user inputted data may have on the prevention of zoonotic disease. The assigned and/or adjusted values can be compiled to generate a risk assessment score, which can be used to determine a food safety index score and/or food safety plan.

ORAL VACCINE

NºPublicación:  EP4673456A1 07/01/2026
Solicitante: 
UNIV MUENSTER WESTFAELISCHE WILHELMS [DE]
Westf\u00E4lische Wilhelms-Universit\u00E4t M\u00FCnster
CN_120677168_A

Resumen de: CN120677168A

The present invention relates to a non-viable bacterial cell in which an immunogenic polypeptide fused to an autotransporter comprising a transmembrane linker and a transporter domain is displayed on the surface of the cell, as well as to formulations comprising such non-viable cells. The formulations are useful as oral vaccines.

MICROBIALS FOR BACTERIAL INHIBITION

NºPublicación:  MX2025014302A 07/01/2026
Solicitante: 
MICROBIAL DISCOVERY GROUP LLC [US]
MICROBIAL DISCOVERY GROUP, LLC
WO_2024254478_A2

Resumen de: MX2025014302A

The invention relates to direct-fed microbials for use in <i>E. coli, Salmonella, </i>and/or <i>Clostridium</i> inhibition in animals. More particularly, the invention relates to isolated <i>Bacillus</i> strains CM256 (NRRL No. B-67706), CM857 (NRRL No. B-67705), CM978 (NRRL No. B-67703), CM1004 (NRRL No. B-67708), and MDG1607 (NRRL No. B-67666), and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention also relates to the use of isolated <i>Bacillus</i> strains CM256 (NRRL No. B-67706), CM857 (NRRL No. B-67705), CM978 (NRRL No. B-67703), and CM1004 (NRRL No. B-67708), and strains having all of the identifying characteristics of these strains, to treat plants having diseases caused by <i>E. coli, Salmonella, </i>and/or <i>Clostridium</i>.<u> </u>

Primer set for detecting pathogens causing Salmonella Enteritis in pigs and Method for detecting pathogens using the same

NºPublicación:  KR20260003546A 07/01/2026
Solicitante: 
충북대학교산학협력단
KR_20260003546_PA

Resumen de: KR20260003546A

본 발명은 돼지 살모넬라성 장염 유발 병원균을 검출할 수 있는 프라이머 세트에 관한 것으로, 본 발명에 따른 프라이머 세트를 이용하여 중합효소 연쇄반응을 통해 돼지 살모넬라성 장염 유발 병원균을 신속, 정확하게 검출할 수 있고, 검출한계가 낮아 소량의 돼지 가검물 시료로부터 병원균을 검출하여 감염병을 조기에 진단할 수 있다.

OMVOGENIC OUTER MEMBRANE PROTEIN ENGINEERING FOR OUTER MEMBRANE VESICLE PRODUCTION

NºPublicación:  WO2026006835A1 02/01/2026
Solicitante: 
THE MEDICAL COLLEGE OF WISCONSIN INC [US]
THE TRUSTEES OF THE UNIV OF PENNSYLVANIA [US]
BRIGHAM AND WOMENS HOSPITAL INC [US]
THE MEDICAL COLLEGE OF WISCONSIN, INC,
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,
BRIGHAM AND WOMEN'S HOSPITAL, INC

Resumen de: WO2026006835A1

Disclosed are engineered outer membrane proteins (OMPs) that comprise one or more extracellular loops from the Salmonella enterica serovar Typhimurium protein PagC or a functional portion thereof. Methods of expressing the engineered outer membrane proteins in a cell, such as a Gram-negative bacteria, to increase the production of outer membrane vesicles are also provided.

一种增强TLR5配体活性的鞭毛蛋白突变体及其应用

NºPublicación:  CN121248735A 02/01/2026
Solicitante: 
兰州大学
CN_121248735_PA

Resumen de: CN121248735A

本发明属于生物技术领域,具体涉及一种具有增强TLR5配体活性的鞭毛蛋白突变体及其应用。选择鼠伤寒沙门氏菌鞭毛蛋白一个氨基酸突变位点,通过定点突变技术,利用大肠杆菌系统表达重组蛋白,经体外实验验证显示出良好的生物学活性,与野生型鞭毛蛋白突变体相比,能够更好的激活TLR5配体活性,为增强鞭毛蛋白佐剂和疫苗活性提供了良好的基础。

一种改良型鞭毛蛋白及其应用

NºPublicación:  CN121248736A 02/01/2026
Solicitante: 
兰州大学
CN_121248736_PA

Resumen de: CN121248736A

本发明属于生物技术领域,具体涉及一种能够增强人源TLR5结合亲和力的鼠伤寒沙门菌鞭毛蛋白及其应用。本发明通过筛选并确定鞭毛蛋白的关键氨基酸突变位点,采用定点突变技术在大肠杆菌系统中实现重组表达。经体外实验验证,该衍生物能够显著激活TLR5配体功能。本发明解决了现有鞭毛蛋白在激活人源TLR5活性方面效果有限的问题,为鞭毛蛋白在疫苗、免疫治疗剂以及放射防护剂领域的应用提供了新的技术方案和理论基础。

一种将猪霍乱沙门氏菌进行低内毒化改造的方法及其应用

NºPublicación:  CN121227763A 30/12/2025
Solicitante: 
中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心)
CN_121227763_PA

Resumen de: CN121227763A

一种将猪霍乱沙门氏菌进行低内毒化改造的方法及其应用,它涉及疫苗领域,本发明通过基因工程技术对猪霍乱沙门氏菌弱毒株SC014的lipid A修饰,对猪霍乱沙门氏菌进行低内毒素化改造,成功构建了低内毒素的猪霍乱沙门氏菌突变体。改造后的猪霍乱沙门氏菌及其外膜囊泡在显著降低内毒素活性的同时,仍能有效激活免疫反应,实现了安全性与有效性的兼顾,为开发新型疫苗提供了新的思路和方法。

SUBSTITUTED 2-AMINOBENZIMIDAZOLES ANALOGS AS ANTIBIOFILM AGENTS

NºPublicación:  US2025387373A1 25/12/2025
Solicitante: 
OHIO STATE INNOVATION FOUND [US]
NORTH CAROLINA STATE UNIV [US]
Ohio State Innovation Foundation,
North Carolina State University
US_2024156788_PA

Resumen de: US2025387373A1

In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

VACCINE COMPOSITION COMPRISING A SYSTEM FOR DELIVERING AN INACTIVATED WHOLE BACTERIUM VIA CATIONIC POLYSACCHARIDE NANOPARTICLES WITHOUT ANY ADJUVANT

NºPublicación:  EP4665313A1 24/12/2025
Solicitante: 
VAXINANO [FR]
Vaxinano
CN_120712079_A

Resumen de: CN120712079A

The present invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition comprising killed intact bacteria intended for use in mammals and birds, said bacteria being wrapped with a cationic agent, in particular cationic nanoparticles.

PRIMER AND PROBE FOR DETECTING SALMONELLA PULLORUM, AND KIT

NºPublicación:  WO2025255902A1 18/12/2025
Solicitante: 
HANGZHOU INSTITUTE FOR ADVANCED STUDY UNIV OF CHINESE ACADEMY OF SCIENCES [CN]
\u56FD\u79D1\u5927\u676D\u5DDE\u9AD8\u7B49\u7814\u7A76\u9662
WO_2025255902_A1

Resumen de: WO2025255902A1

A primer and probe for detecting Salmonella pullorum, and a kit. The primer comprises SP-F and SP-R for detecting the target sequence of the Salmonella pullorum (SP) citE2 gene, and the probe is modified with a fluorescent reporter group and a fluorescent quenching group. By means of providing the primer pair of SP-F and SP-R, which pair specifically binds to the target sequence of the citE2 gene, and combining the primer pair with the probe, whic is used for specific recognition, the accurate and sensitive detection of Salmonella pullorum can be realized.

ANTI-BACTERIAL PROTEIN COMPLEX

NºPublicación:  EP4662223A1 17/12/2025
Solicitante: 
UNIV GLASGOW COURT [GB]
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIV OF OXFORD [GB]
The University Court of the University of Glasgow,
The Chancellor, Masters and Scholars of The University of Oxford
KR_20250160370_PA

Resumen de: MX2025009214A

The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.

ADI Attenuated Salmonella Gallinarum expressing ADI and uses thereof

NºPublicación:  KR20250175381A 17/12/2025
Solicitante: 
주식회사오디세우스바이오
KR_20250175381_PA

Resumen de: KR20250175381A

본 발명은 항암 물질인 아르기닌 디이미나아제 (arginine deiminase; ADI)를 발현하는 항종양 박테리아 균주 및 이의 용도에 관한 것으로, 본 발명에 따른 항암 물질 생산 시스템이 도입된 면역 활성능이 있는 살모넬라 균주는 우수한 면역 항암 효능을 나타내어, 기존 항암제와 함께 또는 독립적으로 암의 치료제로 사용될 수 있다.

一种CeO2-Au复合材料结合TDN-MultiApt形成的MNP-DNA-Apt复合体及制备方法与应用

NºPublicación:  CN121142039A 16/12/2025
Solicitante: 
大连民族大学
CN_121142039_PA

Resumen de: CN121142039A

本发明公开了一种CeO2‑Au复合材料结合TDN‑MultiApt形成的MNP‑DNA‑Apt复合体及制备方法与应用,所述的复合体是通过下述方法制备得到的:先构建立方体c‑CeO2‑Au纳米颗粒,再构建DNA‑CeO2‑Au探针(DA探针),然后利用四个单链DNA样品构建TDN结构,并通过碱基互补配对与适配体Apt链接,形成TDN‑MultiApt;TDN‑MultiApt通过抗原‑抗体反应和碱基互补配对分别与链霉亲和素修饰的磁珠MNP和DA探针结合形成MNP‑DNA‑Apt复合体,即形成MDA探针。本发明中的立方体CeO2‑Au结合TDN‑MultiApt比色传感系统突破了传统的基于培养和其他分子诊断技术的局限性,该系统通过比色模式进行检测,适用于现场快速检测,突出了其作为现场检测解决方案的潜力。

使用减毒鼠伤寒沙门氏菌治疗神经系统肿瘤

NºPublicación:  CN121127262A 12/12/2025
Solicitante: 
总医院公司哈佛大学
CN_121127262_A

Resumen de: WO2024197078A2

Provided herein are compositions and methods for treating benign nervous system tumors, including schwannomas, using attenuated mutants of Salmonella typhimurium comprising a spiC deletion, and, optionally, one or more checkpoint inhibitors.

COMPOUNDS FOR TREATING INFECTIONS

Nº publicación: US2025375435A1 11/12/2025

Solicitante:

OHIO STATE INNOVATION FOUND [US]
Ohio State Innovation Foundation

US_2025375435_PA

Resumen de: US2025375435A1

Disclosed herein are compositions and methods for treating a Salmonella infection. Disclosed herein are compositions and methods for inhibiting FraB in Salmonella. Disclosed herein are methods of increasing 6-phospho-fructose-aspartate within Salmonella bacteria.

traducir